Protein-peptide carrier particle structure in natural whole food form that can be used to improve microcirculation in the eye

Abstract

A protein-peptide carrier particle structure in natural whole food form that can be used to improve microcirculation in the eye, is a granular carrier (01) comprising a core layer (10) and a protective layer (20), wherein the protective layer (20) is provided outside the core layer (10) to prevent the external environment from influencing the activity of the core layer (10), and thus improve the storage stability of the carrier (10) and its absorption rate by the human body; wherein the core layer (10) consists of a composite structure in whole food form of natural buckwheat and contains rutin in combination with protein-peptide carriers.

Description

Field of the invention

[0001] The present invention relates to a carrier structure and in particular to a protein-peptide carrier particle structure in natural whole food form that can be used to improve microcirculation in the eye. State of the art

[0002] The human eye contains numerous arterioles and venules. Ocular microcirculation refers to the blood flow between the arterioles and venules in the eye. This microcirculation transports nutrients and oxygen to the cells, while removing carbon dioxide and other metabolic waste products released by the cells.

[0003] Inadequate oxygen supply to the eye cells and impaired metabolic function are generally referred to as microcirculation disorders in the eye. Such disorders easily lead to symptoms such as eye fatigue, dryness, excessive tearing, premature development of crow's feet, bags under the eyes, dark circles under the eyes, prominent blood vessels in the eye, and possibly visual dysfunctions such as blurred vision, dizziness, and headaches. In severe cases, this can lead to serious eye diseases such as vitreous floaters, dry eye syndrome (keratoconjunctivitis sicca), increased intraocular pressure, glaucoma, cataracts, or retinal detachment. Such microcirculation disorders in the eye are often associated with the aging process, arteriosclerosis-related occlusion of the central retinal artery, and a blockage of the retinal microvascular supply.

[0004] Eye fatigue and dryness can be caused by excessive eye strain, dry eye syndrome, or other eye diseases.

[0005] Excessive tear flow is medically known as epiphora. This means that tears do not drain properly, accumulating at the eyelid margins and causing watery eyes or visible tearing.

[0006] The cause of blurred vision is usually excessive use of the eyes without sufficient rest and inadequate nutrient intake. This temporarily reduces the ability to focus. Other possible causes include cataracts, myopia, dry eye syndrome, glaucoma, uveitis, or age-related degeneration of the focusing function.

[0007] The appearance of small, moving objects in the field of vision, such as small dots, threads, insect-like structures, or dust particles, is called vitreous floaters. These are small, aggregated opacities or cell fragments in the vitreous that are projected onto the retina. Eye movements cause a shift in the vitreous, creating the impression of floating particles in the field of vision.

[0008] Dry eye syndrome is a condition characterized by inadequate lubrication of the eyes. Other symptoms include allergic reactions, redness, increased eye discharge, rapid eye fatigue, and possible blurred vision. Object of the invention

[0009] The main objective of the present invention is to provide a protein-peptide carrier particle structure in natural, whole-food form that can be used to improve microcirculation in the eye. To achieve the above objective, the present invention utilizes the following technical solutions: A protein-peptide carrier particle structure in natural whole food form that can be used to improve microcirculation in the eye is a granular carrier comprising a core layer and a protective layer, wherein the protective layer is provided outside the core layer to prevent the external environment from affecting the activity of the core layer and thus improve the storage stability of the carrier and its absorption rate by the human body, wherein the core layer is composed of a composite structure in whole food form of natural buckwheat and contains rutin in combination with protein-peptide carriers.

[0010] Compared with the conventional technique, with the innovative and unique design of the present invention, the protective layer serving as a covering layer can significantly extend the shelf life and maintain the activity by avoiding damage caused by the external environment, so as to achieve the industrial applicability of maintaining the activity and functionality of the core layer and increasing its absorption rate and product efficacy. Brief description of the drawings Fig. 1 shows a schematic perspective view with partial cross section according to the first embodiment of the present invention; Fig. 2 shows a sectional view according to a first embodiment of the present invention; Fig. 3 shows a sectional view according to a second embodiment of the present invention; Fig. 4 shows a front view according to a third embodiment of the present invention; Fig. 5 shows a perspective view according to a fourth embodiment of the present invention; Fig. 6 shows a perspective view according to a fifth embodiment of the present invention. Detailed description of the implementation examples

[0011] The figures show exemplary embodiments of the protein-peptide carrier particle structure according to the invention in natural, whole-food form, which can be used to improve microcirculation in the eye. The following description only illustrates exemplary embodiments of the invention and is not to be understood as a limitation of the claims.

[0012] It is based on the Fig. 1 and Fig. 2. The first embodiment of the protein-peptide carrier particle structure in natural whole food form, which can be used to improve microcirculation in the eye, represents a granular carrier 01 comprising a core layer 10 and a protective layer 20, wherein the protective layer 20 is provided outside the core layer 10 to prevent the external environment from influencing the activity of the core layer 10, and thus improve the storage stability of the carrier 01 and its absorption rate by the human body.

[0013] The core layer 10 consists of a composite structure in whole food form made from natural buckwheat and contains rutin in combination with protein-peptide carriers.

[0014] The composition of the protective layer 20 includes proteins such as pea protein, corn protein, yeast protein and potato protein.

[0015] The protective layer 20 serving as a covering can significantly extend the durability of the core layer 10 and maintain its activity by avoiding damage caused by the external environment, so as to achieve the industrial applicability of maintaining the activity and functionality of the core layer 10 and increasing its absorption rate and product effectiveness.

[0016] Rutin (C 27 H 30 0 16Rutin, also known as rutoside, is found naturally in plants such as those in the knotweed family, e.g., buckwheat, pollen, red wine, mint, garlic, fennel, etc. Rutin and quercetin have similar chemical structures. Rutin is a glycoside of quercetin, which is converted to quercetin by hydrolysis using the enzyme rutin glucosidase. Rutin belongs to the bioflavonoid family and possesses numerous health-promoting properties, including: inhibition of platelet aggregation, anti-inflammatory and antioxidant effects, strengthening of microvasculature, reduction of atherosclerosis, and a reduced risk of heart disease and hypertension. In addition, rutin acts synergistically with vitamin C in collagen synthesis and is particularly valued for its pronounced antioxidant capacity.

[0017] Rutin strengthens capillaries, prevents capillary fragility, capillary leakage, and capillary bleeding, and helps with venous insufficiency and venous reflux. When applied to the eye, it can relieve symptoms such as eye fatigue, bleeding (e.g., due to retinal venous occlusion), macular edema, ocular hypertension, or diabetic optic nerve damage. In summary, rutin exhibits reparative effects on the optic nerve and the vessels of the eye.

[0018] A prospective, randomized, double-blind study in France investigated the effect of a rutin derivative (troxerutin) on retinal vein occlusions. A total of 53 subjects, including 27 with central retinal vein occlusion and 26 with branch retinal vein occlusion, were randomly assigned to treatment with troxerutin or a placebo. The results showed that, compared to the placebo group, visual acuity, macular sensitivity, retinal circulation time, and macular edema were significantly improved in the troxerutin group. Furthermore, compared to the control group, the progression of ischemia and red blood cell aggregation were reduced in the troxerutin group, suggesting that troxerutin has an improving effect on visual acuity, macular and retinal blood flow velocity, retinal ischemia, and abnormal red blood cell aggregation.

[0019] In an animal study conducted in Turkey, the protective effect of rutin on neuropathy was investigated. In the experiment, 30 rats were divided into five groups: C (healthy control group), MTX (methotrexate, a chemotherapeutic agent), MTM (methotrexate + methanol), MTME (methotrexate + methanol + ethanol), and MTMR (methotrexate + methanol + rutin). The results of pathological analysis (destruction, hemorrhage, congestion, edema, reduction of oligodendrocytes and astrocytes) showed that the MTMR group was similar to the healthy control group, with the most severe pathological changes observed in the MTM group, followed by the MTME group.Pathological analysis showed that the MTX group exhibited moderate focal destruction and hemorrhage with reduced astrocyte and oligodendrocyte counts; the MTM group exhibited severe destruction, edema, a reduction in astrocyte and oligodendrocyte counts, and vasodilation; and the MTME group exhibited mild hemorrhage, edema, and mild vasodilation and congestion. The experiment also revealed that the optic nerve tissue in the MTMR group was similar to that in the healthy control group. These results suggest that rutin, through its anti-inflammatory effects and reduction of oxidative stress, can prevent methanol-induced optic neuropathy and can be used to preserve vision.

[0020] Various physiological reactions in the human body lead to the formation of free radicals. When free radicals cannot be metabolized normally and accumulate excessively in the body, they impair the functions of cells and organs and lead to a variety of aging symptoms and damage, such as wrinkles, spots, inflammatory reactions, chronic diseases, metabolic syndrome, cancer, etc.

[0021] Experiments have shown that rutin has strong antioxidant capacity and its activity is concentration-dependent. In a DPPH radical scavenging assay, rutin achieved an inhibition rate of 90.4% at a concentration of 0.05 mg / ml, compared to 92.8% for ascorbic acid (vitamin C) and 58.8% for butylhydroxytoluene (BHT).

[0022] As a bioflavonoid, rutin supports the absorption and utilization of vitamin C, stabilizes collagen structure, and acts synergistically with vitamin C. This combination improves microcirculation, promotes vascular elasticity, maintains vascular permeability, and supports the patency of blood vessels. A particularly significant effect is seen on capillaries. Therefore, rutin can alleviate symptoms related to vascular weakness, such as varicose veins, bruises, hemorrhoids, bleeding gums, and high blood pressure.

[0023] Rutin has a neuroprotective function and protects nerve cells from damage or cell death caused by free radicals, thus contributing to the prevention of neurodegenerative diseases. Currently, rutin is known to reduce pro-inflammatory cytokines, increase the activity of antioxidant enzymes, downregulate the mRNA expression of pro-apoptotic genes, upregulate the expression of ion transporters and anti-apoptotic genes, and restore the activity of mitochondrial enzymes. These mechanisms of action make rutin a valuable nutrient for neuroprotection and the maintenance of normal brain function.

[0024] The present invention contributes to promoting microcirculation in the eye and can thus improve symptoms such as eye fatigue, excessive tearing, and blurred vision. Furthermore, it can alleviate the symptoms associated with myopia, hyperopia, presbyopia, and degenerative changes in the macular region.

[0025] It will be Fig. 3. The difference between the second embodiment and the first embodiment is that the carrier 01 further comprises an enteric layer 30, wherein the enteric layer 30 is provided between the core layer 10 and the protective layer 20 to prevent the core layer 10 from being destroyed by the gastric acid present in the human digestive tract, thereby further improving the absorption rate of the core layer 10 in the human body.

[0026] The composition of the enteric layer 30 includes pectin, trehalose, polyunsaturated fatty acids and acidic amino acids.

[0027] Fig. 4, Fig. 5 and Fig. 6 show the third embodiment, the fourth embodiment, and the fifth embodiment, respectively. The third embodiment, the fourth embodiment, and the fifth embodiment each comprise a packaging structure 02 and a plurality of supports 01, as described in embodiment 1 or 2. The supports 01 are arranged within the packaging structure 02.

[0028] The present invention thus provides a protein-peptide carrier particle structure in natural whole food form that can be used to improve microcirculation in the eye, which is a granular carrier comprising a core layer and a protective layer, wherein the protective layer is provided outside the core layer to prevent the external environment from affecting the activity of the core layer and thus improve the storage stability of the carrier and its absorption rate by the human body, wherein the core layer consists of a composite structure in whole food form of natural buckwheat and contains rutin in combination with protein-peptide carriers.In this way, the protective layer acting as a coating can significantly extend the shelf life and maintain the activity by avoiding damage caused by the external environment, so as to maintain the activity and functionality of the core layer and improve the absorption rate and product efficacy.

Claims

[1] A protein-peptide carrier particle structure in natural whole food form that can be used to improve microcirculation in the eye is a granular carrier (01) comprising a core layer (10) and a protective layer (20), wherein the protective layer (20) is provided outside the core layer (10) to prevent the external environment from affecting the activity of the core layer (10), and thus improve the storage stability of the carrier (10) and its absorption rate by the human body; wherein the core layer (10) consists of a composite structure in whole food form of natural buckwheat and contains rutin in combination with protein-peptide carriers. [2] A protein-peptide carrier particle structure in natural whole food form which can be used to improve microcirculation in the eye according to claim 1, wherein the composition of the protective layer (20) comprises proteins such as pea protein, corn protein, yeast protein and potato protein. [3] A protein-peptide carrier particle structure in natural whole food form which can be used for improving microcirculation in the eye according to claim 1, wherein the carrier (01) further comprises an enteric layer (30), the enteric layer (30) being provided between the core layer (10) and the protective layer (20) to prevent the core layer (10) from being destroyed by gastric acid in the human digestive tract, thereby further improving the absorption rate of the core layer (10) in the human body. [4] A protein-peptide carrier particle structure in natural whole food form which can be used to improve microcirculation in the eye according to claim 3, wherein the composition of the enteric layer (30) comprises pectin, trehalose, polyunsaturated fatty acids and acidic amino acids.

Images